Get to know us in this short, 2-minute video.
From advanced molecular infectious disease diagnostics to high-throughput and high-velocity RT-PCR testing, Sensiva provides the science, technology, and infrastructure to power large-scale health initiatives for our clients and partners around the world.
Combining decades of infectious disease research and laboratory experience while utilizing molecular testing and high-throughput and high-velocity RT-PCR testing, we provide the science, technology, and infrastructure to power large-scale health initiatives for our clients around the world.
From medical grade plastic injection molding to climate and humidity controlled high-speed medical device assembly, we are proud to be an end-to-end, 100% in-house, American made FDA Registered and ISO Certified lateral flow device and qualitative / quantitative diagnostic testing kit manufacturer.
Sensiva was founded on medical technology. Our suite of software solutions range from LIS systems to provider and patient portals, patient-facing mobile apps, dynamic sample sorting and logistics technology solutions, algorithmic decision-making engines, patent pending risk stratification systems, and beyond.
Sensiva is committed to sourcing high-quality American components, manufacturing our own American-made testing kits, and doing our part to ensure the safety of our customers and workforce. From our Corporate HQ in New Orleans, our high throughput (CLIA) molecular laboratory in Marrero, and our brand new state of the art manufacturing facility in Maple Grove, Minnesota, we are proudly American Made.
We are proud to announce our direct integration and partnership with PointClickCare on the PCC Marketplace!
We produce various types of diagnostic testing kits in our state of the art 50,000sqft manufacturing facility located in Maple Grove, Minnesota.
If you’d like to learn more about Sensiva, please complete this form and we’ll be in touch.
According to Florida’s Department of Health (DOH), Florida Governor Ron DeSantis on Tuesday ordered state health agencies to cut their ties with Quest Diagnostics, one of the country’s largest test labs, after the company failed to report nearly 75,000 coronavirus tests in a timely manner. Most of the unreported tests, the DOH said, are two-weeks old and some date back as many as five months. Similar backlogs with other labs are occurring in states throughout the U.S.
It’s one thing to have false positive, but false negative – that’s when you’re failing the patient. At the height of the breakout, I didn’t believe any result. I looked at the patients and told them, this result is negative but I’m still going to treat you because you have all the symptoms.
Sensiva can provide Caribbean healthcare providers with risk exposure information and guidance immediately after results are received via an online report, or by phone through Sensiva’s proprietary mobile application. While both clearly explain the test results, a team of telemedicine professionals will also be available to answer questions via live chat, email, or phone support.
Cormeum Lab Services LLC, a high-volume Clinical Laboratory Improvement Amendments (CLIA) certified medical lab based in Marrero, Louisiana, recently received approval of its Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a PCR-based SARS-CoV-2 test. In addition, based on the approximately 175 clinical samples submitted to the FDA as part of its EUA approval process, Cormeum's testing solution received a 100% accuracy rating for both specificity and sensitivity.
Sensiva has sought expedited examination of its patent application, and through its affiliate Cormeum Lab Services, LLC, has filed for Emergency Use Authorization through the U.S. Food and Drug Administration.
As a company solely focused on COVID-19 testing, and that is aggressively adding throughput, Sensiva currently has the ability to manufacture, deliver and process over 100,000 tests per week and anticipates having the ability to increase up to 500,000 tests per week within approximately the next 45 days.
